Screening of the siGPCR library in combination with cisplatin against lung cancers

[1]  Soochong Kim,et al.  An Insight into GPCR and G-Proteins as Cancer Drivers , 2021, Cells.

[2]  Sukjoon Yoon,et al.  Q-omics: Smart Software for Assisting Oncology and Cancer Research , 2021, Molecules and cells.

[3]  Suwen Zhao,et al.  G protein-coupled receptors: structure- and function-based drug discovery , 2021, Signal Transduction and Targeted Therapy.

[4]  Sukjoon Yoon,et al.  Analysis of Cross-Association between mRNA Expression and RNAi Efficacy for Predictive Target Discovery in Colon Cancers , 2020, Cancers.

[5]  L. Fournel,et al.  Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer. , 2019, Cancer letters.

[6]  Euna Jeong,et al.  Dissecting phenotypic responses of the druggable targetome in cancers , 2019, Scientific Reports.

[7]  M. Bordoloi,et al.  Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection. , 2019, Current drug targets.

[8]  R. Stevens,et al.  Crystal structure of the Frizzled 4 receptor in a ligand-free state , 2018, Nature.

[9]  D. Ni,et al.  Gemcitabine and cisplatin for treatment of lung cancer in vitro and vivo. , 2018, European review for medical and pharmacological sciences.

[10]  Paul A. Insel,et al.  G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? , 2018, Molecular Pharmacology.

[11]  David E. Gloriam,et al.  Trends in GPCR drug discovery: new agents, targets and indications , 2017, Nature Reviews Drug Discovery.

[12]  C. Lindskog,et al.  A pathology atlas of the human cancer transcriptome , 2017, Science.

[13]  Antoine de Weck,et al.  Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening , 2017, Cell.

[14]  Ann E. Sizemore,et al.  Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.

[15]  T. Shimo,et al.  Tachykinin Receptor 3 Distribution in Human Oral Squamous Cell Carcinoma. , 2016, Anticancer research.

[16]  G. Mills,et al.  Loss-of-function screens of druggable targetome against cancer stem–like cells , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  Jing Wang,et al.  ER stress and autophagy are involved in the apoptosis induced by cisplatin in human lung cancer cells , 2016, Oncology reports.

[18]  Sukjoon Yoon,et al.  Analysis of image-based phenotypic parameters for high throughput gene perturbation assays , 2015, Comput. Biol. Chem..

[19]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[20]  G. Nowak,et al.  Assessment of mitochondrial functions and cell viability in renal cells overexpressing protein kinase C isozymes. , 2013, Journal of visualized experiments : JoVE.

[21]  Kun Tao,et al.  CLPTM1L Is Overexpressed in Lung Cancer and Associated with Apoptosis , 2012, PloS one.

[22]  Günter P. Wagner,et al.  Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples , 2012, Theory in Biosciences.

[23]  Karol Kozak,et al.  Z’ Factor including siRNA design quality parameter in RNAi screening experiments , 2012, RNA biology.

[24]  Katherine S. Lovejoy,et al.  Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. , 2010, Genes & development.

[25]  N. Williams,et al.  ATP Synthase Is Responsible for Maintaining Mitochondrial Membrane Potential in Bloodstream Form Trypanosoma brucei , 2006, Eukaryotic Cell.

[26]  Douglas G Altman,et al.  The logrank test , 2004, BMJ : British Medical Journal.

[27]  D G Altman,et al.  Survival probabilities (the Kaplan-Meier method) , 1998, BMJ.